---
title: "OSR Holdings Grants BCME Exclusive Global VXM01 Rights"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284814884.md"
description: "OSR Holdings has signed a global exclusive license agreement with BCM Europe AG, granting BCME rights to develop and commercialize VXM01, a cancer immunotherapy, for up to $815 million in milestone payments and royalties. BCME will fund all development and commercialization efforts, while OSR will receive 100% of future royalties after BCME recoups its investment. The deal, approved by OSR's board, aims to align interests and limit OSR's direct development costs. OSR Holdings focuses on advancing biomedical innovations and is listed on Nasdaq as OSRH."
datetime: "2026-04-30T17:29:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284814884.md)
  - [en](https://longbridge.com/en/news/284814884.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284814884.md)
---

# OSR Holdings Grants BCME Exclusive Global VXM01 Rights

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

OSR Holdings ( (OSRH) ) has provided an update.

On April 29, 2026, OSR Holdings signed a global exclusive license agreement with largest shareholder BCM Europe AG, granting BCME worldwide rights to develop and commercialize VXM01, a Phase 3‑ready oral VEGFR‑2‑targeting cancer immunotherapy, in return for up to $815 million in milestone payments, downstream royalties, and an option requiring BCME to purchase up to $15 million of OSR stock. In a related April 29, 2026 transaction, BCME and affiliates agreed to pledge their entire approximately 29.7% OSR stake—9,974,728 shares—as collateral securing milestone obligations, while OSR moves to acquire full VXM01 intellectual property from subsidiary Vaximm for $30 million, a structure that tightens alignment between the company and its largest shareholder and underscores confidence in VXM01’s commercial potential.

The agreement is structured so BCME funds all development, regulatory, and commercialization work, including any sublicenses, with OSR to receive 100% of future royalties after BCME recoups its investment and preferred return. Governance, IP, and termination terms are described as customary, and the related‑party deal was approved by OSR’s board, including independent directors, after an external fairness opinion, positioning OSR to capture long‑term value from VXM01 while limiting its direct development spend.

**More about OSR Holdings**

OSR Holdings, Inc. is a global healthcare holding company focused on advancing biomedical innovations in health and wellness through subsidiaries active in immuno-oncology, regenerative biologics, and medical device technologies. The company, listed on Nasdaq under the ticker OSRH, seeks to improve health outcomes worldwide by developing and commercializing novel therapeutic platforms and related technologies.

**Average Trading Volume:** 1,025,533

**Technical Sentiment Signal:** Hold

**Current Market Cap:** $15.24M

For a thorough assessment of OSRH stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [OSRH.US](https://longbridge.com/en/quote/OSRH.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)
- [OSRHW.US](https://longbridge.com/en/quote/OSRHW.US.md)

## Related News & Research

- [How Chubb’s (CB) New Canada Cancer Coverage Launch Could Reframe Its Health Benefits Strategy](https://longbridge.com/en/news/286787301.md)
- [Cel-Sci Forms Multikine Commercialization Partnership in Middle East](https://longbridge.com/en/news/286482219.md)
- [Health Rounds: Widely used asthma drug may improve performance of cancer immunotherapies](https://longbridge.com/en/news/286957357.md)
- [15:31 ETRenowned IP Trial Lawyer Joins Latham & Watkins in Bay Area](https://longbridge.com/en/news/286957828.md)
- [BCAL Diagnostics Expands National Access to Early Cancer Detection Blood Tests](https://longbridge.com/en/news/286850851.md)